當一顆藥在實驗室裡完美無瑕，為什麼進入工廠卻可能全盤崩潰？ 當專利保護的是「藥是什麼」，那麼誰在守護「藥怎麼做出來」？ 當全球多功能蛋白不到 1.6% 能成功走入臨床，漢康如何跨越放大生產的死亡之谷？ 本集我們邀請到漢康生技 CMC 舵手——執行總監 郭孟薇 博士（Vivian），深入解析從 DNA 到 IND 僅 13 個月背後的工藝革命。
精彩內容：
CMC 的商業底層邏輯： 為什麼國際 Big Pharma 買的是「確定性」而不是「可能性」？
授權金背後的關鍵籌碼： 為什麼成熟的 CMC 數據包能直接拉高國際談判桌上的估值？
死亡之谷的真相： 為何細胞從杯子大小放大到上萬公升反應槽時，失敗風險會指數級上升？
99% 純度的意義： 當法規前期 90% 即可接受，漢康為何選擇在第一階段就做到接近上市等級？
成本與病患的平衡點： 高產量（3–6 g/L）與高回收率如何同時壓低定價並維持健康毛利？
【About This Episode】 When a drug performs flawlessly in the lab, why can it collapse during scale-up? If patents protect what a drug is, who protects how it is made? And when fewer than 1.6% of tri-functional biologics make it to clinical stage, how does HanchorBio cross the so-called “valley of death”? In this episode, Dr. Vivian Kuo, Head of CMC at HanchorBio, reveals the industrial strategy behind achieving >99% purity, 3–6 g/L yield, multi-year stability, and a rapid 13-month timeline from DNA to IND. CMC is not just manufacturing—it is the second moat that determines whether a promising molecule becomes a global medicine.
【Key Takeaways】 The Commercial Logic of CMC: Why do global pharmaceutical giants buy certainty instead of possibility? Licensing Leverage: How can a robust CMC package significantly increase valuation at the negotiation table? The Valley of Death in Scale-Up: Why does moving from lab-scale to industrial bioreactors dramatically increase the risk of failure? What 99% Purity Really Means: Why exceed early-stage regulatory requirements and aim for near-commercial standards from day one? Balancing Affordability and Profitability: How do high yield and high recovery rates enable both accessible pricing and sustainable margins?
Podden och tillhörande omslagsbild på den här sidan tillhör
漢康生技. Innehållet i podden är skapat av 漢康生技 och inte av,
eller tillsammans med, Poddtoppen.
